Article
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML).
Leukemia - 1 May 2021
Patkar Nikhil, Kakirde Chinmayee, Shaikh Anam Fatima, Salve Rakhi, Bhanshe Prasanna, Chatterjee Gaurav, Rajpal Sweta, Joshi Swapnali, Chaudhary Shruti, Kodgule Rohan, Ghoghale Sitaram, Deshpande Nilesh, Shetty Dhanalaxmi, Khizer Syed Hasan, Jain Hasmukh, Bagal Bhausaheb, Menon Hari, Khattry Navin, Sengar Manju, Tembhare Prashant, Subramanian Papagudi, Gujral Sumeet
Abstract excerpt
We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission, and evaluated MRD using sensitive error-corrected next generation sequencing (NGS-MRD) and multiparameter flow cytometry (FCM-MRD) at the end of induction (PI) and consolidation (PC). Nearly 71% of patients were PI NGS-MRD+ and 40.9% PC NGS-MRD+ (median VAF 0.76%). NGS-MRD+ patients had a significantly higher...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.